Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503099 | 0.78 | PIK3CA (0.60) | PIK3CAPOLBPIK3R1 | |
| SCHEMBL30503085 | 0.78 | PIK3CA (0.63) | PIK3CAPIK3R1 | |
| SCHEMBL25402946 | 0.78 | PIK3CA (0.60) | PIK3CAPOLBPIK3R1 | |
| SCHEMBL25403044 | 0.78 | PIK3CA (0.63) | PIK3CAPIK3R1 | |
| SCHEMBL25622241 | 0.75 | CTSL (0.39) | PIK3CAPIK3R1MTORPIK3CG | |
| SCHEMBL25256747 | 0.74 | PIK3CA (0.51) | PIK3CAPOLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31277403 | 0.74 | PIK3CA (0.51) | PIK3CAPOLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25622238 | 0.74 | PIK3CA (0.39) | PIK3CAPIK3R1RAD52MTORALDH1A1 | |
| SCHEMBL30447239 | 0.74 | PIK3CA (0.45) | PIK3CAPOLBPIK3R1ITKMTOR | |
| SCHEMBL25222499 | 0.74 | PIK3CA (0.45) | PIK3CAPOLBPIK3R1ITKMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-05-08 | — | — | US | disclosed |
| CN-118946360-A | Bicyclic heteroarenes and methods of use thereof | 奇尼塔公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-4444317-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107623-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | TARDBP, TDP2, PSEN2 | PIK3CA 4005/4885POLB 843/4885PIK3R1 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.